Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country 1
Phase
Study type
15 / 777 trials
PostedSponsorStudyPhaseStatus
17 Nov 2026NS Pharma, Inc.United States, Australia, CanadaA Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyPhase 2Enrolling By Invitation12 Nov 2026Novo Nordisk A/SUnited States, Argentina, BrazilA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothPhase 3Not Yet Recruiting12 Nov 2026Novo Nordisk A/SUnited States, China, JapanA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePhase 3Not Yet Recruiting12 Nov 2026Novo Nordisk A/SUnited States, Brazil, ChinaA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothPhase 3Not Yet Recruiting10 Nov 2026Boehringer IngelheimBelgium, France, GermanyA Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigPhase 3Not Yet Recruiting10 Nov 2026Eli Lilly and CompanyUnited States, France, JapanA Study of LY4336619 in Adult Participants With Advanced Solid TumorsPhase 1Not Yet Recruiting9 Nov 2026Boehringer IngelheimJapanReal-world Outcome of Zongertinib in Japan (J-HERZ)Not Yet Recruiting9 Nov 2026Boehringer IngelheimUnited States, Belgium, FinlandA Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentPhase 2Not Yet Recruiting9 Nov 2026Boehringer IngelheimUnited States, Australia, JapanA Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationPhase 1Not Yet Recruiting5 Nov 2026Novo Nordisk A/SUnited States, Argentina, AustraliaA Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityPhase 3Not Yet Recruiting4 Nov 2026Boehringer IngelheimUnited States, Argentina, AustriaA Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Phase 3Not Yet Recruiting3 Nov 2026Metagen Therapeutics, Inc.United States, JapanSafety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)Phase 1, Phase 2Recruiting30 Oct 2026Juro Sciences Inc.JapanA Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)Phase 2Recruiting28 Oct 2026Eli Lilly and CompanyUnited States, Argentina, AustraliaA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskPhase 3Not Yet Recruiting20 Oct 2026Metcela Inc.JapanLong-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart DiseaseRecruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.